Profiling of pyrrolizidine alkaloids using a retronecine-based untargeted metabolomics approach coupled to the quantitation of the retronecine-core in medicinal plants using UHPLC-QTOF.
Alkanna
Metabolomics
Profiling
Pyrrolizidine alkaloids
Retronecine
UHPLC-HRMS quantification
Journal
Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336
Informations de publication
Date de publication:
05 Feb 2023
05 Feb 2023
Historique:
received:
23
09
2022
revised:
07
11
2022
accepted:
16
11
2022
pubmed:
3
12
2022
medline:
7
1
2023
entrez:
2
12
2022
Statut:
ppublish
Résumé
Pyrrolizidine alkaloids (PA) are secondary metabolites of high toxicological relevance. Several PA quantitative methodologies were developed based on a limited number of certified standards, including time consuming solid phase extraction (SPE) purification steps. Herein, we shed light on the variability of PA in herbal extracts and propose a quantification methodology based on ultra-high-performance liquid chromatography high-resolution mass spectrometry (UHPLC-HRMS) for the evaluation of the total PA content as retronecine-equivalents (RE) directly from crude matrices. Particularly in the focus of the investigation were Alkanna spp. (Boraginaceae), which possess a wide range of pharmaceutical properties. In addition, a comparative PA screening of crude and SPE enriched extracts was performed and PA-containing plants from Fabaceae and Compositae families were included to demonstrate universal applicability. In total, 105 PA were identified using HRMS
Identifiants
pubmed: 36459765
pii: S0731-7085(22)00592-1
doi: 10.1016/j.jpba.2022.115171
pii:
doi:
Substances chimiques
retronecine
2P5723M6II
Pyrrolizidine Alkaloids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115171Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.